Leeds Teaching Hospitals NHS Trust

Running trials

• Recruiting

  Physical Activity Promotion and Clinical Remission in Severe Asthma

  NCT07735494· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Source

• Not yet recruiting

  Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

  NCT06240403· Phase 2· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Source

• Recruiting

  Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences

  NCT06774014· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Source

• Not yet recruiting

  The U.K. NorthStar Clinical Network

  NCT06711692· Source

• Recruiting

  Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart

  NCT06505798· Source

• Active, not recruiting

  A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

  NCT06713135· Phase 4· Source

• Recruiting

  A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

  NCT06547840· Phase 1· Source

• Recruiting

  The Force Frequency Relationship in Heart Failure and Diabetes Mellitus: a Metabolic Aetiology?

  NCT07309523· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Source

• Recruiting

  Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis

  NCT06728956· Source

• Active, not recruiting

  Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

  NCT06230354· Phase 2· Source

• Recruiting

  An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

  NCT06435000· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Source

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Source

• Recruiting

  DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution

  NCT05389774· Source

• Active, not recruiting

  Registry on Percutaneous Electrochemotherapy

  NCT05267080· Source

• Recruiting

  UK Heart Failure With Preserved Ejection Fraction

  NCT05441839· Source

• Recruiting

  A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

  NCT05613023· Phase 3· Source

• Active, not recruiting

  Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

  NCT05524883· Phase 1/2· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382286· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Source

• Recruiting

  A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT05085028· Phase 3· Source

• Active, not recruiting

  COVID-19 Antibody Responses In Cystic Fibrosis

  NCT04863573· Source

• Recruiting

  (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  NCT04996875· Phase 2· Source

• Recruiting

  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

  NCT05065216· Phase 2/3· Source

• Active, not recruiting

  A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· Phase 3· Source

• Active, not recruiting

  ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

  NCT04695080· Phase 2/3· Source

• Recruiting

  Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

  NCT04965298· Phase 3· Source

• Active, not recruiting

  The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)

  NCT04573881· Source

• Recruiting

  A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Phase 1/2· Source

• Active, not recruiting

  Cancer Surveillance and Support

  NCT04749862· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

  NCT04640623· Phase 2· Source

• Recruiting

  A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

  NCT03969329· Phase 3· Source

• Recruiting

  ICONIC: Improving Outcomes Through Collaboration in OsteosarComa

  NCT04132895· Source

• Active, not recruiting

  A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

  NCT03821610· Phase 2· Source

• Active, not recruiting

  Study of Tumour Focused Radiotherapy for Bladder Cancer

  NCT02447549· Phase 2· Source

• Active, not recruiting

  Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02227251· Phase 2· Source

• Active, not recruiting

  IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

  NCT01398085· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure4 recruiting
• Childhood cancers2 recruiting
• Lung cancer2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukemia1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

  NCT06532032· Phase 1/2· Source

• Completed

  Cue X as a Treatment for People With Parkinson's Disease

  NCT05794542· Source

• Completed

  The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy

  NCT05432232· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· Source

• Terminated

  Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

  NCT04632940· Phase 3· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Source

• Completed

  A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

  NCT03992430· Phase 3· Source

• Completed

  CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

  NCT04226248· Phase 3· Source

• Completed

  Limitations of Aerobic Capacity in Chronic Heart Failure

  NCT04332536· Source

• Completed

  The MOCA I Study - Microvascular Obstruction with CoFI™ System Assessment

  NCT03654573· Phase 1· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Source

• Completed

  Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

  NCT03644303· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source

• Completed

  Long-term Follow-up Gene Therapy Study for RPGR- XLRP

  NCT04312672· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Source

• Completed

  Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT02500381· Phase 3· Source

• Completed

  Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

  NCT02461888· Phase 2· Source

• Completed

  PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

  NCT02423603· Phase 2· Source